AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Nexalin Technology, Inc.
Video analysis: NXL
All videosNo video analysis for this stock yet. Request one from our team.
News: NXL
Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer's Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer's Pilot Study
Further analysis of ADAS-Cog data from the Company's randomized, sham-controlled clinical trial — previously published in the Journal of Alzheimer's Disease and in Radiology — identifies specific improvements in cognitive domains associated with memory in Alzheimer's patients
Nexalin Technology Announces Reverse Stock Split
HOUSTON, TX, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), announces that its board of directors has approved a 1-for-30 reverse stock split of the Company's common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company's stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios.
Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company's Proprietary DIFS™ Platform
Dr. Victor Fontenelle Bastos de Lima, an investigator on Nexalin's recently completed Brazilian clinical study, received the Young Researcher Award at BRAIN 2026 – Congress on Brain, Behavior and Emotions, held in Porto Alegre, Brazil
Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life
Accepted abstracts showcase Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform and clinical improvements across anxiety, depression, insomnia and quality of life
Similar companies
-
Enlivex Therapeutics Ltd.
ENLV
·
NASDAQ
Compare
-
Retractable Technologies, Inc.
RVP
·
New York Stock Exchange Arca
Compare
-
CollPlant Biotechnologies Ltd.
CLGN
·
NASDAQ
Compare
-
Harvard Bioscience, Inc.
HBIO
·
NASDAQ
Compare
-
Vicarious Surgical Inc.
RBOT
·
Other OTC
Compare
-
Modular Medical, Inc.
MODD
·
NASDAQ
Compare